OCC.ASX: Q4 FY26 ASX Investor Presentation

Q4 FY26 ASX Investor Presentation

Stock	Orthocell Ltd (OCC.ASX)
Release Time	14 Jul 2026, 8:47 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Orthocell Ltd Q4 FY26 Investor Presentation

Key Points

Record revenue of $13.2M for FY26, up 44% YoY
Strong growth in U.S. commercialization of Remplir
Expansion of distributor network to 20+ states
Appointment of a Thai distributor for Remplir
Strong growth in Australian adoption of Remplir

Full Summary

Orthocell Ltd's Q4 FY26 Investor Presentation highlights a 44% year-on-year revenue growth to $13.2M for FY26, with strong commercialization of Remplir in the U.S., where the company's distributor network has expanded to 20+ states. The presentation also notes the appointment of a Thai distributor for Remplir, continued strong growth in Australian adoption of the product, and a significant expansion of the company's global footprint. The company anticipates a material uplift in U.S. revenue in the upcoming quarters, with a strong liquidity position and sufficient cash runway to support ongoing commercial execution and R&D activities.

Guidance

FY26 revenue of $13.2M, up 44% YoY; Q4 FY26 revenue of $3.8M, up 20% QoQ

Outlook

Orthocell Ltd anticipates a material uplift in U.S. revenue in the upcoming quarters, with continued expansion of its global footprint and commercialization of Remplir.